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Background. Human bone marrow stromal/stem cells (hMSCs, also known as the skeletal stem cells or mesenchymal stem cells) are
being employed to study lineage fate determination to osteoblasts, adipocytes, and chondrocytes. However, mechanistic studies
employing hMSC have been hampered by the difficulty of deriving genetically modified cell lines due to the low and unstable
transfection efficiency. Methods. We infected hMSC with a CRISPR/Cas9 lentivirus system, with specific inducible dCas9-
coupled transcription activator or repressor: dCas9-KRAB or dCas9-VP64, respectively, and established two hMSC lines
(hMSC-CRISPRi and hMSC-CRISPRa) that can inhibit or activate gene expression, respectively. The two cell lines showed
similar cell morphology, cell growth kinetics, and similar lineage differentiation potentials as the parental hMSC line. The
expression of KRAB-dCas9 or VP64-dCas9 was controlled by the presence or absence of doxycycline (Dox) in the cell culturing
medium. To demonstrate the functionality of the dCas9-effector hMSC system, we tested controlled expression of alkaline
phosphatase (ALP) gene through transfection with the same single ALP sgRNA. Results. In the presence of Dox, the expression
of ALP showed 60-90% inhibition in hMSC-CRISPRi while ALP showed more than 20-fold increased expression in hMSC-
CRISPRa. As expected, the ALP was functionally active and the cells showed evidence for inhibition or enhancement of in vitro
osteoblast differentiation, respectively. Conclusion. hMSC-CRISPRi and hMSC-CRISPRa are useful resources to study genes and
genetic pathways regulating lineage-specific differentiation of hMSC.
1. Background
Human bone marrow stromal/stem cells (hMSCs, also
known as human skeletal or mesenchymal stem cells) are
clonal cells present within the bone marrow stroma and are
capable of differentiation into various mesoderm-type line-
age cells, e.g., osteoblasts, adipocytes and chondrocytes [1].
hMSC has been extensively employed to study the molecular
mechanisms of lineage commitment and differentiation and
to identify novel factors regulating differentiation processes
[2]. We have previously employed global methods of proteo-
mics and transcriptomics to identify specific factors and sig-
naling pathways controlling hMSC differentiation [3–6].
However, follow-up studies focusing on specific factors or a
signaling pathway have been hampered by the difficulty in
achieving stable hMSC lines that either are deficient or over-
express the target genes of interest at a specific time point of
differentiation stages. Moreover, conventional viral mediated
gene overexpression in hMSC is technically expensive and
time-consuming.
Type II CRISPR-Cas9 system (Clustered Regularly Inter-
spaced Palindromic Repeats–CRISPR-associated 9) is a novel
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and powerful technology to manipulate gene expression. It is
developed from the bacterial immune system for cleaving
foreign DNA [7] and is composed of Cas9 endonuclease
and a target-identifying CRISPR RNA (single guide RNA,
sgRNA). The sgRNA targets a 18-25 base pair sequence of
target gene and thus guides Cas9 to specific DNA sites where
it creates a blunt-ended double-stranded break (DSB) within
the sequence by its endonuclease activity [8, 9]. This DSB
induces the generation of mutations that may cause a frame-
shift in gene coding sequence [10, 11]. Alternatively, it can
supply a repair template with homology to the cut site and
facilitates targeted integration of mutation or insertion [12].
Besides the direct gene code editing, the CRISPR-Cas9
system can be employed for studying genetic and epigenetic
regulation. The Cas9-sgRNA complex can act as a scaffold
to recruit different transcription effectors to specific DNA
sequences, allowing gene transcription regulation with either
transcriptional activation (CRISPRa) or repression (CRIS-
PRi). This function requires disruption of Cas9 nuclease
activity by introducing mutations into two nuclease domains
(the RuvC and HNH domains) of Cas9 resulting in a
deactivated-Cas9 (dCas9) [13–15]. Artificial transcription
factors (effector) fused with dCas9 to form the dCas9-
effector and then paired with specific sgRNA can be used to
target different genes. Different effector proteins, such as
transcription activators or repressors fused to dCas9, can dif-
ferently activate (CRISPRa) or interfere (CRISPRi) in gene
expression. In addition, the CRISPR-dCas9 system can be
coupled with inducible systems allowing dynamic control of
gene transcription [16].
In the present study, we examined the possibility of
developing universal hMSC lines to be employed for studies
of specific gene activation or inhibition. We employed a sys-
tem where dCas9 is fused with two different transcription
effectors for either activation or inhibition of gene transcrip-
tion. One effector is the VP64 activator, an engineered tetra-
mer of the herpes simplex VP16 transcriptional activator
domain, which can activate silent genes or upregulate active
genes in mammalian cells [16–19]. The second effector is a
transcriptional repressor KRAB (Krüppel-associated box)
domain of Kox1, an efficient repressor of gene transcription
[20]. By infecting hMSC with dCas9-VP64 or dCas9-KRAB
lentiviral vectors, respectively, we selected and obtained two
hMSC lines to be employed for an easy and quick approach
for the activation or inhibition of targeted genes by transfect-
ing targeted sgRNA, and we also showed that the regulation
of gene expression is inducible by addition or removal of
doxycycline (Dox) in cell culture medium.
2. Methods
2.1. Cell Culture. As a model for primary hMSC, we
employed the telomerized hMSC line (hMSC-TERT) which
was developed in our lab [21]. The hMSC-TERT was created
from primary hMSC derived from the bone marrow sample
obtained from a young healthy donor, through stable overex-
pression of human telomerase reverse transcriptase gene
(hTERT). The hMSC-TERT cells express all known markers
of hMSC and “stemness” characteristics in vitro and in vivo
[21, 22]. For the rest of the manuscript, we will refer to the
cell line as hMSC. HEK293T is a human cell line, derived
from the HEK 293 cell line and expressing a mutant version
of the SV40 large T antigen, and was employed to produce
recombinant viruses. Cells were cultured in Minimum Essen-
tial Medium (MEM) with 10% fetal bovine serum (FBS) and
penicillin-streptomycin (P/S) (1%). All cell culture reagents
were purchased from Life Technologies (Taastrup, Den-
mark). All the remaining chemicals were purchased from
Sigma-Aldrich (Copenhagen, Denmark). Cells were incu-
bated in 5% CO2, at 37
°C with a humidity of 95%.
2.2. Lentiviral Vector Production. In order to create inducible
CRISPRa cell line, we employed Tet-regulable dCas9-VP64
lentiviral expression vector (pHAGE TRE dCas9-VP64-HA,
Addgene, plasmid #50916) [23]; and for inducible CRISPRi
cell line, Tet-regulable dCas9-KRAB lentiviral expression
vector was utilized (dCas9-TRE-KRAB-HA, Addgene, plas-
mid #50917) [23]. We also employed two plasmids that
express lentivirus envelope proteins for lentiviral packaging
and production (psPAX2 and pCMV-VSV-G, Addgene,
#12259 and #8454).
HEK293T packaging cells were cultured in MEM with
10% FBS with 1% P/S until 50-60% confluence. The culture
medium was changed to fresh prewarmed growth medium
(without P/S) 2 hours prior to transfection. We prepared
transfection DNA mixture containing dCas9-effector fusion
vector, psPAX2, and pCMV-VSV-G (ratio 4 : 3 : 1) in Opti-
mum Medium (Thermo Fisher Scientific, Roskilde, Den-
mark) and polyethyenimine (PEI) (1μg/μl in 1x PBS,
pH4.5) at a ratio of 4 : 1 of PEI :DNA. The mixture was
incubated for 5-10min at room temperature and added
gradually to the cells. The cells were incubated for 6-8
hours in 3.5% CO2 in a 37
°C cell incubator. The medium
was then replaced with fresh growth medium (3% FBS,
with 25mM HEPES) and incubated for 10 hours and mixed
with sodium butyrate (10mM). The cells continue in
culture for 48 hours posttransfection.
Cell culture media were pooled from HEK293-
transfected cells and stored at 4°C as the 1st medium. Fresh
growth medium was added (with the addition of 25mM
HEPES), and the cells were incubated overnight (60-72 hours
posttransfection). The 2nd medium was collected and pooled
with the 1st medium. One μg DNase I and 1μl of 1M MgCl2
per ml of viral supernatant were added, and the mixture was
incubated at room temperature for 30min to digest any
carry-over plasmid DNA; this was followed by incubation
at 4°C for 2-4 hours. The supernatants were filtered through
a 0.45μm low protein binding filter and utilized in virus puri-
fication step. We employed the virus particle purification
steps as described in [24]. Briefly, viral particles were
obtained by ultracentrifugation; i.e., the collected medium
supernatants were centrifuged at 80,000 g for 2 hours at 4°C
using a 20% sucrose cushion. The supernatant was discarded
without disturbing the pellets. Fresh collected medium
supernatants were added, and a second centrifugation step
was performed. Finally, the viral pellet collected from
100ml conditioned medium, was suspended in 200μl of 1x
HBSS buffer.
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2.3. Lentiviral Transduction. hMSC line was transduced with
lentiviral particles according Addgene’s protocol (https://
www.addgene.org/protocols/generating-stable-cell-lines/).
Briefly, hMSCs were seeded and cultured until 70% conflu-
ence and infected using a range of multiplicities of infection
(MOIs) (5.0 to 10.0) of the lentivirus in MEM supplemented
with 8μg/ml polybrene. The cells were incubated for 48
hours, and the supernatant media was discarded to remove
excess virus particles. For selection, 400μg/ml G418 (Genet-
icin) was used for positive section of the infected hMSC and
this treatment continued for 5-7 days until all control cells
(un-transduced) died. The cells were then trypsinized, and
selection was continued for 2-3 weeks using culture in
medium containing G418 for in order to obtain stable and
pure transduced cell populations.
2.4. Alkaline Phosphatase (ALP) gRNA Design, Synthesis, and
Transfection.Human ALP gRNA for transcription regulation
was designed in an online CRISPR design tool (http://crispr
.mit.edu) based on ALP promoter sequence, from -200 bp
to +0 bp. The selected ALP gRNA oligo (TCGTGGCACGA
CCGGCCCGCGGG) and the universal tracrRNA oligo
(Alt-R® CRISPR-Cas9 tracrRNA) were synthesized at Inte-
grated DNA Technologies (Leuven, Belgium). The gRNA-
tracrRNA guide complex was mixed as a final duplex of
10μM in nuclease-free duplex buffer (Integrated DNA Tech-
nologies) and denatured by heating at 95°C for 5min and
then allowed to form the heteroduplexes by slowly cooling
to 23°C. hMSC-CRISPRi or hMSC-CRISPRa was transfected
with ALP crRNA-tracrRNA guide complex employing Dhar-
maFECT™ Transfection Reagent (Dharmacon Inc./VWR
International A/S, Søborg, Denmark) according to the man-
ufacturer’s instructions (http://dharmacon.gelifesciences
.com/uploadedFiles/Resources/basic-dharmafect-protocol
.pdf).
2.5. Lipofectamine 2000 Cell Transfection and Electroporation
Transfection. To compare the efficiency of gRNAs, siRNA
and plasmid inhibition or overexpression in hMSCs utilizing
Lipofectamine® 2000 or electroporation were performed to
compare with the sgRNA transfection in hMSC-CRISPRi or
hMSC-CRISPRa. Alkaline phosphatase (ALP) Silencer®
Select validated siRNA was purchased from Ambion (App.-
Bio) (#4390821); pcDNA3-Alkaline phosphatase (ALP) plas-
mid was purchased from PPL (Public Protein/Plasmid
Library, Jiangsu, China, #BC009647). siRNA transfection
was performed by Lipofectamine® 2000 (Thermo Fisher Sci-
entific, Roskilde, Denmark) as the manufacturer’s instruc-
tions suggested for siRNA transfection in cells (https://
assets.thermofisher.com/TFS-assets/LSG/manuals/
Lipofectamine_2000_Reag_protocol.pdf). The plasmid
transfection in hMSCs was performed by electroporation by
Nucleofector™ 2b Device (Lonza, BioNordika Denmark
A/S). Briefly, hMSCs were harvested and suspended with
Human MSC Nucleofector Solution (Lonza, #VAPE-1001)
at the concentration of 5 × 105 cells/100μl, mixed with 2μg
plasmid DNA, and transferred into the electroporation
chamber, using program U-23. This was immediately
followed by the addition of 500μl of the prewarmed culture
medium containing serum and supplements; cells were then
transferred into the prepared 6-well plates and, after 2 hours,
were changed to fresh cell culturing medium.
2.6. Osteoblastic Differentiation. hMSCs were cultured to
reach 80-90% confluence and then incubated in osteoblastic
induction medium (OIM) containing 10% FBS, 1% Pen–
Strep, 10mM β-glycerophosphate, 50μg/ml 2-phosphate
ascorbate, 10 nM dexamethasone, and 10nM 1,25-dihydrox-
yvitamin D3. OIM medium was replaced every 3 days.
2.7. Adipogenic Differentiation. hMSCs were cultured to
reach 95-100% confluence prior to adding adipogenic induc-
tion medium (AIM) containing MEM medium supple-
mented with 10% FBS, 10% horse serum, 1% Pen–Strep,
100 nM dexamethasone, 0.45mM isobutyl methyl xanthine,
3μg/ml insulin, and 1μM rosiglitazone (Cayman,
#BRL49653). The AIM medium was replaced every 2 days.
2.8. Chondrogenic Differentiation. For chondrogenesis in
hMSCs, 250,000 MSCs were centrifuged at 500 g, 7min in
15ml tubes to form pellets at high-density culture. Chondro-
genesis was induced for 18 days with MEM medium supple-
mented with 50μg/ml L-ascorbic acid-2-phosphate (Sigma-
Aldrich.), 1% ITS+1 (BD Bioscience), 10-7M dexamethasone
(Sigma-Aldrich), and 10ng/ml TGFb3 (R&D Systems, Wies-
baden, Germany). The aggregated cells were cultured in
tubes with 0.5-1ml medium/pellet at 37°C in a humidified
atmosphere containing 95% air and 5% CO2. The medium
was replaced every other day for 18 days [25].
2.9. Alkaline Phosphatase (ALP) Activity Assay. Cell viability
was determined on day 7 of osteoblastic differentiation by
Cell Titer-Blue cell viability assay according to the manufac-
turer’s instructions (Promega, Nacka, Sweden). Staining
intensity was measured at 579/584 by a FLUO star Omega
plate reader (BMG Laboratories, Germany). ALP activity
was determined by incubating the cells with 1mg/ml of p-
nitro phenyl phosphate in 50mMNaHCO3 and 1mMMgCl2
buffer (pH 9.6) at 37°C for 20min. The activity was stopped
by the addition of 3M NaOH. The reaction absorbance was
measured at 405nm by a FLUO star Omega plate reader,
and ALP activity was corrected for variation in cell number.
2.10. Alkaline Phosphatase Staining. Alkaline phosphatase
(ALP) staining was performed at day 7 postinduction.
The cells were rinsed with PBS and fixed in acetone/citrate
(1.5 : 1, vol : vol) buffer (pH4.2) for 5min at room temper-
ature. The cells were incubated for 1 hour at room tem-
perature with ALP staining substrate solution containing
0.2mg/ml naphthol AS-TR phosphate dissolved in distilled
water (1 : 5) and 0.417mg/ml Fast Red dissolved in 0.1M
Tris buffer.
2.11. Oil Red O Staining. Mature adipocyte formation was
visualized on day 12 of adipocytic differentiation by staining
lipid droplets with Oil Red O. Cells were washed with
phosphate-buffered saline (PBS), fixed with 4% paraformal-
dehyde for 10min, and then incubated with fresh-made
and filtered (0.45μM) Oil Red O in 60% isopropanol solution
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for 1 hour at room temperature. Images were acquired using
an inverted Zeiss microscope.
2.12. Alcian Blue Staining. To evaluate the synthesis of
cartilage-specific proteoglycans, sulfated glycosaminoglycans
(GAGs) were stained with Alcian blue. Cell pellets from day
18 chondrogenic differentiation were fixed and embedded
by paraffin; samples were deparaffinized and hydrated to dis-
tilled water, stained in 1% Alcian blue 8-GX (Sigma-Aldrich)
in 3% acetic acid in pH 2.5, and then rinsed in distilled water
as previously described [26]. The accumulation of GAGs was
assessed using microscopic examination.
2.13. Protein Sample Preparation and Western Blot Analysis.
For Western blot analysis, we used whole cell lysates. The
cells were washed in PBS and lysed in RIPA buffer (Thermo
Fisher Scientific) supplemented with a protease inhibitor
(Roche, Switzerland). Samples were centrifuged for 10min
at 13,000 rpm (4°C). Protein concentration was determined
with a BCA kit (Thermo Fisher Scientific), and equal
amounts of proteins were loaded on a polyacrylamide gel
(Thermo Fisher Scientific). Blotted nitrocellulose membranes
were incubated overnight with HA-tag primary antibody
(Santa Cruz Biotechnology). The blots were developed after
1-hour incubation with secondary anti-rabbit horseradish
peroxidase-conjugated antibody (Santa Cruz Biotechnology)
using an ECLWestern blotting kit (Thermo Fisher Scientific)
and Kodak films.
2.14. Quantitative Real-Time PCR (qRT-PCR). RNA from
cells was isolated at day 2 of osteoblastic differentiation by
TRIzol® according to the manufacturer’s instructions
(Thermo Fisher Scientific). The first strand complementary
DNA was synthesized from 1μg total RNA by Revert aid
cDNA kit (Sigma-Aldrich). RT-qPCR was performed by
ABI StepOne™ Real time PCR machine with SYBR green
(Thermo Fisher Scientific). The data was normalized to geo-
metric means of reference genes and analyzed by a compara-
tive CTmethod where Δ-CT is the difference between the CT
values of the target and geometric mean of reference genes.
PCR Primers for human ALP gene are as follows: ACGT
GGCTAAGAATGTCATC (forward) and ACGTGGCTA
AGAATGTCATC (reverse); and primers for GAPDH are
as follows: GGCGATGCTGGCGCTGAGTAC (forward)
and TGGTTCACACCCATGACGA (reverse).
2.15. Statistical Analysis. Data were collected from at least 3
independent experiments with each experiment comprising
duplicates or triplicates. A one-way analysis of variance
(AVOVA) test with the nonparametric Kruskal-Wallis test
was used to assess statistical differences in the groups by
GraphPad Prism 7.0. Data was expressed as the mean
and standard deviation (SD), and P < 0:05 was considered
as significant.
3. Results
3.1. Generation of Inducible CRISPRi or CRISPRa hMSC. As
shown in Figure 1(a), hMSCs were transduced with lentivirus
expressing dCas9-KRAB (CRISPRi) or dCas9-VP64 (CRIS-
PRa), which express the CRISPR-dCas9 fused with gene tran-
scription repressor (KRAB) or activator (VP64), respectively,
and the expression is driven from a doxycycline- (Dox-)
inducible promoter (TRE promoter) [23]. After lentiviral
transduction, cells were selected with G418 for 21-28 days
in order to obtain stable expression cells (Figure 1(a)). In
the absence of Dox, no expression of dCas9-KRAB or
dCas-VP64 was detectable in inducible CRISPRi hMSC or
CRISPRa hMSC, but when increasing concentrations of
Dox adding into the culture medium, there were rapid and
dose-dependent increases in their expression reaching a peak
at a concentration of 1000ng/ml (Figure 1(b)). To further
prove the dynamic control of dCas9 expression in both cell
lines, Dox was removed from culture medium after two-day
incubation which led to the disappearance of dCas9 protein
expression in both hMSC-CRISPRi and hMSC-CRISPRa
within 1-2 days (Figures 1(c) and 1(d)).
3.2. Characterization of Inducible CRISPRi and CRISPRa
hMSCs. In the presence of Dox, lentivirus-transduced
hMSC-CRISPRi and hMSC-CRISPRa retained spindle-
shaped fibroblast-like morphology of the parental hMSC line
(Figure 2(a)). We observed no difference in cell proliferation
rate between the cell lines in the presence or absence of Dox
in 12 days culturing, as evidenced by determination of cell
number and cell viability (Figure 2(b)). Following osteoblast
(OB) differentiation induction, hMSC-CRISPRi and hMSC-
CRISPRa maintained osteoblast differentiation capacity as
evidenced by positive staining for ALP and induction of
ALP activity (Figure 2(c)). Similarly, both cell lines differen-
tiated readily to adipocytes or chondrocytes as compared to
the parental cell line (Figures 2(d) and 2(e)).
3.3. Dynamic Inducible Control of ALP Transcription in
hMSC-CRISPRi or hMSC-CRISPRa. To test for regulating
gene expression of specific genes in hMSC-CRISPRi or
hMSC-CRISPRa, we chose alkaline phosphatase (ALP) gene
as a candidate for its known role in osteoblast (OB) differen-
tiation of hMSC [27]. One ALP gRNA was designed, and het-
eroduplexes were produced and transfected into hMSC-
CRISPRi or hMSC-CRISPRa, respectively. After delivery in
hMSC-CRISPRi, the expression level of ALP showed no
change in the absence of Dox; in the presence of increasing
concentrations of Dox, the gene expression of ALP exhibited
dose-dependent inhibition; this was also confirmed by ALP
staining (Figure 3(a)). Conversely, the expression levels of
ALP gene and ALP staining were significantly increased in
hMSC-CRISPRa in the presence of Dox in a dose-
dependent fashion (Figure 3(b)).
3.4. Regulation of Osteoblast Differentiation of hMSC by
Changes in ALP Gene Expression. To further validate the
functional relevance of gene regulation in hMSC-CRISPRi
or hMSC-CRISPRa, we compared the osteoblast differentia-
tion capacity in hMSC-CRISPRi or hMSC-CRISPRa follow-
ing transfection with ALP gRNA or negative gRNA
(control (Ctrl)). We observed that in the absence of Dox,
there were no differences at ALP activities in control gRNA
and ALP gRNA-transfected hMSC-CRISPRi or hMSC-
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CRISPRa (Figures 3(c) and 3(d)), while in presence of Dox,
the activity of ALP was significantly repressed in hMSC-
CRISPRi or increased in hMSC-CRISPRa, and this was asso-
ciated with decreased (Figures 3(c)) or increased
(Figure 3(d)) ALP staining.
3.5. High Efficiency of Gene Inhibition or Activation in
Inducible CRISPRi and CRISPRa hMSCs. To determine the
efficiency of specific gene inhibition or activation by gRNA
in hMSC-CRISPRi and hMSC-CRISPRa, we compared the
gene inhibition with traditional siRNA transfection by Lipo-
fectamine 2000 and the gene overexpression with traditional
plasmid transfection by electroporation that we had tested
before as the most efficient transient transfections in hMSCs.
As shown in Figure 4, both specific siRNA and gRNA trans-
fections in CRISPRi hMSC have significant gene inhibition
on day 2 (>90%) or day 7 (>75-85%) after cell transfection
(Figures 4(a) and 4(b)). On the other hand, the gene activa-
tion by gRNA in CRISPRa hMSC was shown to be much
stronger than traditional plasmid overexpression (31-fold
vs 2.5-fold on day 2 after transfection) (Figure 4(c)), and
the gene activation by gRNA in CRISPRa hMSCs also lasted
much longer: 7 days posttransfection, cells demonstrated 10
times overexpression while the plasmid-transfected overex-
pression effects disappeared (Figure 4(d)).
4. Discussion
Human bone marrow stromal/stem cells (hMSC) are multi-
potent cells with the ability to differentiate into osteogenic,
chondrogenic, and adipogenic lineages. The cells have been
utilized in molecular studies aimed at understanding the
molecular mechanisms controlling lineage fate determina-
tion through targeting specific genes or genetic pathways
[3, 5, 28]. Manipulating gene expression in hMSC by plasmid
transfection is the most common approach. However, this
approach requires specific expensive electroporation instru-
ments or employing relatively toxic chemical formulations,
and it usually exhibits low efficiency (usually <25% in our
laboratory). Conversely, viral gene delivery is the most effi-
cient way to attain stable gene expression in hMSC; however,
this method requires specific laboratory setup, with time-
consuming and technical difficulties.
In the present study, we employed CRISPR-dCas9 tech-
nology and created two universal hMSC lines to be utilized
in specific gene transcriptional inhibition or transcriptional
dCas9 TRE-KRAB
lentivirus
dCas9 TRE-VP64
lentivirus
hMSC-Tert
cell line
or
Inducible
CRISPRi hMSC
Inducible
CRISPRa hMSC
G418 selection
(a)
dCas9-KRAB-HA
Actin
+ Dox (ng/ml)
Inducible CRISPRi hMSC
–Dox 100 500 1000 2000
–Dox 100 500 1000 2000
+ Dox (ng/ml)
Actin
Inducible CRISPRa hMSC
dCas9-VP64-HA
(b)
Wash out
dCas9-KRAB-HA
Actin
Inducible CRISPRi hMSC
2 2 3 4 6 days
–Dox +Dox –Dox
(c)
–Dox
2 2 3 4 6 days
+Dox –Dox
Wash out
dCas9-VP64-HA
Actin
Inducible CRISPRa hMSC
(d)
Figure 1: Generation of inducible CRISPRi and CRISPRa hMSCs. (a) Illustration and flow chart for generating inducible CRISPRi using
dCAs9 TRE-KRAB and CRISPRa using dCas9 TRE-VP64. (b) Western blot analysis of expression of dCas9-KRAB-HA and dCas9-VP64-
HA in the presence of increasing concentrations of doxycycline (Dox) in CRISPRi-hMSC and CRISPRa-hMSC, separately. The effect of
the absence or presence of Dox on protein expression of dCas9-KRAB-HA (c) or dCas9-VP64-HA (d). CRISPRi-hMSC and CRISPRa-
hMSC were cultured in cell culturing medium with or without Dox (0 or 1000 ng/ml) for 2 days, then washed twice by PBS and changed
the cell culturing medium to the medium without Dox, with continuous culturing of the cells till day 6. Cell proteins were harvested on
days 2, 3, 4, and 6 and subjected to Western blots to test the expression of dCas9-KRAB and dCas9-VP64 by HA antibody.
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activation. We demonstrate that this technology did not
affect the growth rate or the functional characteristics of the
cells. Moreover, we demonstrated that regulation of gene
expression can be achieved by the presence Dox in culture
medium that acts as a “switch” to regulate gene expression.
To regulate gene expression, a simple transfection by one
sgRNA for targeting gene was enough to obtain either inhibi-
tion of target gene in hMSC-CRISPRi cells or overexpression
in hMSC-CRISPRa cells (summary as shown in Figure 5).
We employed one transcriptional repressor, KRAB
domain of Kox1, an efficient repressor of gene transcription
[20], to construct with dCas9 and make the hMSC-
Control hMSC InducibleCRISPRi hMSC
Inducible
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Figure 2: Characterization of inducible CRISPRi and CRISPRa human skeletal stem cells (hMSC). (a) The morphology of control hMSC,
inducible hMSC-CRISPRi, or hMSC-CRISPRa. (b) Short-term growth curve of control hMSC, hMSC-CRISPRi, or hMSC-CRISPRa. The
cells were seeded in a 96-well plate and cultured in the absence or presence of doxycycline; cell viability assay was performed at different
time points during 12 days in culture (D0–D12, D= day). (c–e) Control hMSC, hMSC-CRISPRi, and hMSC-CRISPRa were induced to
osteogenic, adipogenic, and chondrogenic differentiation. The cells were cultured for 7 days in osteoblast induction medium (OIM) (c), 12
days in adipocyte induction medium (AIM) (d), or 18 days in chondrogenic induction medium (CIM) (e) as described in Methods.
Alkaline phosphatase (ALP) activity and ALP staining (c), Oil Red O staining (d), or Alcian blue staining (e) were performed to visualize
different hMSC lineage-differentiated phenotype. Data are expressed as the means ± SD. Scale bar: 100μm.
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CRISPRi cells, and we obtained 60-99% inhibition efficiency
using only one sgRNA. To further enhance the inhibition
efficiency, previous studies have suggested a number of other
approaches, including screening of several sgRNAs to iden-
tify the most efficient sgRNA [20]; the pooling of several
designed sgRNAs of the targeting gene [16, 29]; or combining
several fusion transcriptional repressors with dCas9 in the
system, such as KRAB, the CS (chromoshadow) domain of
HP1a, the WPRW domain of Hes1, and four concatenated
copies of the mSin3 domain (SID4X) [14, 16]. We observed
that transfection of sgRNAs in CRISPRi cell system resulted
in similar levels of gene expression inhibition compared to
siRNA-mediated gene inhibition. This is expected as both
are small RNA molecules with high transfection efficiency
(usually >95% transfection efficiency got in hMSCs for small
RNA transfection in our laboratory). However, sgRNA-
CRISPRi has the important advantage of the ability to
control gene expression by Dox, allowing gene manipula-
tion at different time points at developmental stages of dif-
ferentiating hMSC.
We observed high efficiency for gene regulation by
CRISPR-dCas9 in CRISPRa our activation system. By simply
transfecting one small molecular sgRNA of the targeting
gene, we routinely obtained 5 to 20-fold overexpression for
the targeting genes in hMSCs. This method is much easier
than the traditional approaches for gene overexpression,
e.g., transfection or infection of gene open reading frame
(ORF) cloning plasmid or viral vectors, respectively. We have
utilized the VP64 activator in the CRISPRa cell system. Other
activator fusion proteins have the employed activation of
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Figure 3: Dynamic regulation of ALP expression during osteoblast differentiation in inducible CRISPRi or CRISPRa hMSC. Inducible CRISPRi
(a) or CRISPRa (b) hMSC were transfected with ALP gRNA oligo by DharmaFECT™ Transfection Reagent and cultured with increasing
concentrations of Dox. ALP expression was measured by RT-qPCR at day 2. Inducible CRISPRi (c) or CRISPRa (d) hMSC was transfected
with ALP gRNA oligo or negative control (Ctrl) and induced to OB differentiation in the absence or presence of Dox (1000ng/ml). ALP
activity and staining (bottom photomicrographs) were performed on day 7 in hMSC-CRISPRi or day 3 in hMSC-CRISPRa to show the most
evident change for inhibition or activation. Data are expressed as the means ± SD. ∗P < 0:05, ∗∗P < 0:01, and ∗∗∗P < 0:001.
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gene expression such as P65 activator, heat shock factor 1
(HSF1), and the viral replication and transcription activator
(RTA) [30]. Among these, VP64 infection was proven to
demonstrate more efficiency than other reported activities
[11]. In addition, several approaches have been described to
further enhance gene activation in CRISPRa system, e.g., fus-
ing multirepeats of one transcriptional activator with dCas9
[20, 31]; combining several different transcriptional activa-
tors together with dCas9 [32]; or using multiple sgRNAs
designed across the targeting gene promoter [19].
One of the most striking advantages for CRISPRi and
CRISPRa is the possibility for simultaneous multigene target-
ing [19, 20, 29]. Through single transfection with several
sgRNAs targeting different genes, the method can inhibit or
enhance multiple genes allowing examination of the com-
bined effects of multigene inhibition or activation. Moreover,
VP64-CRSIPRa and KRAB-CRISPRi hMSC lines can also be
employed in screening a large number of effectors by sgRNAs
libraries. Combing both CRISPRi and CRISPRa together to
study one or several targeting genes by loss-or-gain effects
can further help confirming the specific effects of targeting
factors and limit the bias of function study.
CRISPR/Cas9 technology is a powerful tool for creating
gene knock-ins and knock-outs; however, concerns need to
be addressed consequentially to mutations engendered at
gene sites other than the intended target site (off-target).
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Figure 4: Comparison of the efficiency of gene inhibition or gene activation in control hMSC, inducible CRISPRi hMSC, and CRISPRa
hMSC. (a, b) Control (Ctrl) hMSC and inducible CRISPRi were transfected with siRNA-Ctrl, siRNA-ALP, Ctrl gRNA, or ALP gRNA
oligo and for 2 or 7 days as described in Methods. ALP expression was measured by RT-qPCR at day 2 (a) or day 7 (b). (c, d) Control
(Ctrl) hMSC and inducible CRISPRa were transfected with pcDNA3 vector plasmid, pcDNA3-ALP plasmid by electroporation, or Ctrl
gRNA and ALP gRNA oligo by DharmaFECT™ Transfection Reagent as described in Methods. ALP expression was measured by RT-
qPCR at day 2 (c) and day 7 (d). Data are expressed as the means ± SD. ∗P < 0:05, ∗∗P < 0:01, and ∗∗∗P < 0:001.
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The selection and design of the sgRNA for specific target
genes are the key to control the specificity of targeting in
our system. We suggest initially selecting several highest
scored sgRNAs for the target gene that are designed by differ-
ent programs. Alternatively, commercially proved sgRNAs
(Thermo Fisher Scientific, Merck/Sigma, Takara et al.) are
now available. Pooling of several sgRNAs for one target gene
might improve the inhibition or activation efficiency of the
target gene; however, limiting the number of sgRNAs can
benefit the reduction of off-target effects. If one sgRNA has
a high enough efficiency, we suggest using one sgRNA target-
ing for one gene. Several different sgRNAs for one gene can
be used in different parallel experiments to obtain consistent
results and limit misleading the effects of off-targeted events.
Moreover, besides checking the specific target gene, testing
the several highest potential off-target genes by the gRNAs
can also help to confirm the targeting specificity in the
CRISPR cells.
5. Conclusion
The availability of inducible hMSC-CRISPRi and hMSC-
CRISPRa cell lines makes it possible to investigate the role
of specific genes and genetic pathways at a specific develop-
mental stage of hMSC differentiation and map the genetic
regulatory networks underlying lineage differentiation of
hMSC. These tools can help to enhance our understanding
of hMSC biology and are also relevant to regenerative medi-
cine applications for tissue regeneration.
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DSB: Double-stranded break
KRAB: Krüppel-associated box
hMSC-TERT: Telomerized hMSC line
hTERT: Human telomerase reverse
transcriptase gene
MEM: Minimum Essential Medium
FBS: Fetal bovine serum
P/S: Penicillin-streptomycin
dCas9-TRE-KRAB: Tet-regulable dCas9-KRAB
lentiviral expression vector
pHAGE TRE dCas9-VP64: Tet-regulable dCas9-VP64
lentiviral expression vector
PEI: Polyethyenimine
G418: Geneticin
OIM: Osteoblastic induction
medium
AIM: Adipogenic induction
medium
PBS: Phosphate-buffered saline
qRT-PCR: Quantitative real-time PCR
OB: Osteoblast
Ctrl: Control
CS: Chromoshadow
ORF: Open reading frame.
Data Availability
The data used to support the findings of this study are
included within the article. The materials used to support
the findings of this study are available from the correspond-
ing author upon request.
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Figure 5: The technical flow chart of inducible inhibition or activation-specific genes in CRISPRi or CRISPRa human stromal/stem cells
(hMSCs). Human bone marrow stromal/stem cell line (hMSC-TERT) stable transfected with dCas9 TRE-KRAB or dCas9TRE-VP64 to
establish the inducible CRISPRi or CRISPRa cell lines. In these cells, with simply transfecting the small molecular guide RNAs (gRNAs)
that target different specific genes, it can easily inhibit or activate specific gene expressions with or without doxycycline (Dox) in cell
culturing mediums or differentiation induction medium.
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Additional Points
Highlight. (i) Using the principle of CRISPR technology, we
established two human stromal/stem cell lines: CRISPRi
and CRIPSRa. (ii) These two cells overcome the difficulty of
plasmid transfection in hMSCs and make gene transcription
inhibition and overexpression easily by only transfecting a
small guide RNA (gRNA). (iii) The inhibition and activation
of specific genes have been proved to be highly efficient in
both cell lines. (iv) The transcription regulation in both cell
lines can be controlled by Dox induction at different times
during differentiation.
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